Navigation Links
TorreyPines Therapeutics, Inc. Hires Advisor to Evaluate Strategic Alternatives
Date:4/15/2009

LA JOLLA, Calif., April 15 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced that it has hired Merriman Curhan Ford as its financial advisor to assist in the evaluation of strategic options, including the possible sale of the Company or its assets.

About TorreyPines Therapeutics, Inc.

TorreyPines Therapeutics, Inc. is a biopharmaceutical company committed to providing patients with better alternatives to existing therapies through the research, development and commercialization of small molecule compounds. The company's goal is to develop versatile product candidates each capable of treating a number of acute and chronic diseases and disorders such as migraine, chronic pain, and xerostomia. The company currently has three clinical stage product candidates: two ionotropic glutamate receptor antagonists and one muscarinic receptor agonist. Further information is available at www.tptxinc.com.

This press release contains forward-looking statements or predictions. Such statements are subject to numerous known and unknown risks, uncertainties and other factors, which may cause TorreyPines' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These and other risks which may cause results to differ are described in greater detail in the "Risk Factors" section of TorreyPines' annual report on Form 10-K for the year ended December 31, 2008 and TorreyPines' other SEC reports. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and TorreyPines undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

    Company contact:
    Craig Johnson
    Chief Financial Officer
    TorreyPines Therapeutics, Inc.
    858-623-5665 x 158
    cjohnson@TPTXinc.com



'/>"/>
SOURCE TorreyPines Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. TorreyPines NGX426, an Oral AMPA/Kainate Receptor Antagonist, Meets Primary Endpoints in Reducing Capsaicin-Induced Pain in Healthy Subjects
2. TorreyPines Therapeutics Announces Management Change and Second Quarter 2008 Financial Results
3. TorreyPines Therapeutics Reports First Quarter 2008 Financial Results and Accomplishments
4. TorreyPines Therapeutics Licenses Intellectual Property from Johns Hopkins Related to Novel Uses of Glutamate Receptor Antagonists for Prevention, Treatment of Stroke, Heart Attack
5. Gamma Secretase Modulators Show Promise in Alzheimers Disease Animal Model Efficacy Studies, According to Research Conducted by TorreyPines Therapeutics
6. TorreyPines Therapeutics to Present at BMO Capital Markets Focus on Healthcare Conference
7. TorreyPines Therapeutics to Present at the JMP Securities Healthcare Focus Conference
8. Former Executive at Genzyme Corp. and Osiris Therapeutics, Inc. to Head Business Advisory Board at Rx for Africa, Inc.
9. Oxygen Biotherapeutics, Inc. Establishes Warfighter Division
10. Cell Therapeutics, Inc. (CTI) President Craig Philips to Present at Invest Northwest
11. Cell Therapeutics, Inc. to Offer to Repurchase up to $124 Million of Its Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... ... The Radiology Business Management Association (RBMA) has named the nine winners ... year, are among the most prestigious in radiology marketing because a panel of radiology ... recognize achievements in both large budget (over $5,000) and small budget (under $5,000) campaigns. ...
(Date:3/24/2017)... ... ... The iaedp Foundation, the premier provider of educational programs and training standards ... full spectrum of disordered eating, announced today that the 2017 Symposium set a new ... and several countries converged on the Green Valley Resort in Las Vegas. , ...
(Date:3/24/2017)... Calif. (PRWEB) , ... March 24, 2017 , ... ... raised over $100,000 for its innovative EcoQube Frame vertical micro-veggies garden on ... instant demand for the product – with nearly 2,000 consumers (and counting) already ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... at the Advanced ERISA Benefit Claims Litigation seminar in Chicago, Illinois. She ... Record, The majority of cases litigated under ERISA involve claims for long-term disability ...
(Date:3/24/2017)... ... March 24, 2017 , ... Gastro Health ... partnership to prep patients for colonoscopy at the HyGIeaCare® Center that is to ... Miami, FL. , The HyGIeaCare® Prep, cleared by the U.S. Food ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... March 27, 2017  PhaseRx, Inc. (NASDAQ: PZRX), ... inherited liver diseases in children, today reported financial ... ended December 31, 2016 and provided an update ... continued to make progress during the fourth quarter ... from our non-human primate safety study, and with our ...
(Date:3/27/2017)... HAMILTON, N.J. , March 27, 2017 ... company and leading in vivo pharmacology contract ... Solar Farm adjacent to its newly expanded preclinical research ... The solar farm provides a cleaner, renewable energy source ... on the environment. Completion of the Genesis Solar Farm ...
(Date:3/24/2017)... , March 24, 2017 According to a new report ... and Industry Forecast, 2014-2022," the spine bone stimulators market was valued at $562 ... at a CAGR of 3.6% during the forecast period. ... ... Research Logo ...
Breaking Medicine Technology: